Financial News

Financial Report: Charles River Labs

Manufacturing Support segment drives growth in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Labs
 
4Q Revenues: $353.9 million (+7%)

4Q Earnings: $32.4 million (+17%)

FY Revenues: $1.4 billion (+5%)

FY Earnings: $151.1 million (+18%)

Comments: Revenue for the Research Models and Services segment was $114.7 million in the quarter, down 3%. Discovery and Safety Assessment revenues were $160.5 million, up 7%. Manufacturing Support revenues were $78.6 million, up 26%, reflecting the acquisitions of Celsis and Sunrise Farms, which contributed 14% to revenue growth. Foreign exchange reduced reported revenue growth by 4%.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters